Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 9, 2005, Pages 387-402

  Yang, Zheng ^a   Zadjura, Lisa ^a   D'Arienzo, Celia ^a   Marino, Anthony ^a   Santone, Kenneth ^a   Klunk, Lewis ^a   Greene, Douglas ^a   Lin, Pin Fang ^a   Colonno, Richard ^a   Wang, Tao ^a   Meanwell, Nicholas ^a   Hansel, Steven ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

Author keywords

Animal; HIV attachment inhibitor; In vitro; Pharmacokinetics; Prediction

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ACEBUTOLOL; ANTIRETROVIRUS AGENT; CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; FURAFYLLINE; GLYCOPROTEIN; KETOCONAZOLE; METOPROLOL; PROTEINASE INHIBITOR; QUINIDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFAPHENAZOLE; TIMOLOL; VERAPAMIL;

AEROBIC METABOLISM; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; CANNULATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME INHIBITION; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; KIDNEY CLEARANCE; LIVER CLEARANCE; LIVER MICROSOME METABOLISM; MALE; MONKEY; NONHUMAN; PLASMA PROTEIN BINDING; RAT; STEADY STATE; STRUCTURE ANALYSIS;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 30944443423     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.471     Document Type: Article

References (33)

1. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003; 9: 839-843.
2. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-873.
3. Powderly WG. Limitations of current HIV therapies: opportunities for improvement. J Acquir Immune Defic Syndr 2003; 33: S7-S16.
4. Lin PF, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100: 11013-11018.
5. Wang T, Zhang X, Wallace OB, et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J Med Chem 2003; 46: 4236-4239.
6. Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 147-171.
7. Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58.
8. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407-484.
9. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
10. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel-Dekker: New York, 1982, 409-417.
11. van Kempen GMP, van Vilet LJ. Mean and variance of ratio estimators used in fluorescence ratio imaging. Cytometry 2000; 39: 300-305.
12. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Goodman-Gilman JG, Hardman JG, Limbard LE, Molinoff PB, Ruddon RW (eds). McGraw-Hill: New York, 1996, 1707-1792.
13. Mahmood I. Allometric issues in drug development. J Pharm Sci 1999; 88: 1101-1106.
14. Chiou WL, Robbie G, Chung SM, Wu TC, Ma C. Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm Res 1998; 15: 1474-1479.
15. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245: R768-R774.
16. Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-835.
17. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 1999; 39: 211-238.
18. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmcokinet 2001; 40: 893-905.
19. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47-54.
20. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55: 425-461.
21. Prime-Chapman HM, Fearn RA, Cooper AE, Vanessa M, Hirst BH. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 2004; 311: 476-484.
22. Litman T, Brangi M, Hudson E, et al. The multidrug-resistance phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000; 113: 2011-2021.
23. Oxvegy C, Litman T, Szakaes G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001; 285: 111-117.
24. Ukabam SO, Cooper BT. Small intestinal permeability to mannitol, lactulose, and polyethylene glycol 400 in celiac disease. Dig Dis Sci 1984; 29: 809-816.
25. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996; 48: 1083-1089.
26. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 2000; 17: 1456-1460.
27. Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 2003; 20: 1200-1209.
28. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 1998; 86: 626-633.
29. Chiou WL, Buehler PW. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 2002; 19: 868-874.
30. Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 1998; 15: 1792-1795.
31. Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 2000; 17: 135-140.
32. Tan X, Chu CK, Boudinot FD. Development and optimization of anti-HIV nucleoside analogs and prodrugs: a review of their cellular pharmacology, structure activity relationships and pharmacokinetics. Adv Drug Deliv Rev 1999; 39: 117-151.
33. Fung HB, Stone EA, Piacenti FG. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 2002; 24: 1515-1548.